In the last trading session, 3.67 million shares of the AIM ImmunoTech Inc (AMEX:AIM) were traded, and its beta was 0.37. Most recently the company’s share price was $0.15, and it changed around $0.0 or -4.17% from the last close, which brings the market valuation of the company to $10.12M. AIM currently trades at a discount to its 52-week high of $0.62, offering almost -313.33% off that amount. The share price’s 52-week low was $0.13, which indicates that the current value has risen by an impressive 13.33% since then. We note from AIM ImmunoTech Inc’s average daily trading volume that its 10-day average is 1.35 million shares, with the 3-month average coming to 762.11K.
AIM ImmunoTech Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended AIM as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. AIM ImmunoTech Inc is expected to report earnings per share of -0.09 for the current quarter.
AIM ImmunoTech Inc (AMEX:AIM) trade information
Instantly AIM has showed a red trend with a performance of -4.17% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.1996 on recent trading dayincreased the stock’s daily price by 24.85%. The company’s shares are currently down -25.66% year-to-date, but still down -27.09% over the last five days. On the other hand, AIM ImmunoTech Inc (AMEX:AIM) is -36.93% down in the 30-day period. We can see from the shorts that 0.49 million shares have been sold at a short interest cover period of 1.63 day(s).
AIM ImmunoTech Inc (AIM) estimates and forecasts
The year-over-year growth rate is expected to be -0.99%, down from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 100k in revenue for the current quarter. The company’s sales for the same quarters a year ago were 65k and 40k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 53.85%. Forecasts for the next quarter put sales growth at -100.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 42.86%.
AIM Dividends
AIM ImmunoTech Inc’s next quarterly earnings report is expected to be released in March.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 8.57% of AIM ImmunoTech Inc shares, and 14.07% of them are in the hands of institutional investors. The stock currently has a share float of 15.39%. AIM ImmunoTech Inc stock is held by 33.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 8.2454% of the shares, which is about 4.08 million shares worth $1.52 million.
VANGUARD GROUP INC, with 4.021% or 1.99 million shares worth $0.74 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
